Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

The Instructive Case Of Galena Biopharma
Seeking Alpha
Wednesday, February 26, 2014 - 11:01am
tags:
Galena Biopharma
Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls
Yahoo/Zacks.com
Wednesday, February 26, 2014 - 10:50am
tags:
Onconova, Isis Pharmaceuticals, Vertex Pharmaceuticals, Kalydeco, ISIS-SMNRx, Rigosertib
More than 40 health care, consumer and addiction treatment groups urge FDA to revoke approval of the pain drug Zohydro
CNN
Wednesday, February 26, 2014 - 9:46am
tags:
Zohydro, FDA
DelMar Pharmaceuticals: Following The Former CEO Of Celgene On His Fight Against Brain Cancer
Seeking Alpha
Wednesday, February 26, 2014 - 9:43am
tags:
Celgene, DelMar Pharmaceuticals, VAL-083, glioblastoma multiforme
PLAN B Revisited: FDA Rules on One-Step Exclusivity and ANDA Labeling Carve-Outs
FDA Law Blog
Wednesday, February 26, 2014 - 9:15am
tags:
FDA, exclusivity, ANDAs, Plan B contraceptive, Teva Pharmaceuticals
Even for busy doctors, 'nothing is as good as a rep' for getting pharma info
Fierce Pharma Marketing
Wednesday, February 26, 2014 - 9:12am
tags:
drug reps, physician access, physicians
Novartis to Open Data on Newly Approved Medicines to Researchers
Bloomberg
Wednesday, February 26, 2014 - 9:09am
tags:
Novartis, drug approvals, R&D, clinical trial data
Orexigen Sees Positives In European Application For Contrave
Seeking Alpha
Wednesday, February 26, 2014 - 9:08am
tags:
Contrave, Europe, obesity, Orexigen
Arena Pharmaceuticals, Inc. Earnings: What to Expect Thursday
Motley Fool
Wednesday, February 26, 2014 - 9:07am
tags:
earnings, Arena Pharmaceuticals
Bayer says takeover offer for Algeta successful
Reuters
Wednesday, February 26, 2014 - 9:05am
tags:
Bayer, Algeta, M&A
NewLink's Pancreatic Cancer Vaccine and the Feuerstein-Ratain Rule
TheStreet.com
Wednesday, February 26, 2014 - 9:04am
tags:
pancreatic cancer, vaccine, HyperAcute Pancreas, NewLink Genetics
Tiny Northwest Biotherapeutics aims to dominate brain cancer
Yahoo/Reuters
Wednesday, February 26, 2014 - 8:41am
tags:
Northwest Biotherapeutics, DCVax-L, brain cancer
Merck Abandons Once-Promising Experimental Cancer Drug to Ariad
Wall St Cheat Sheet
Tuesday, February 25, 2014 - 6:15pm
tags:
Merck, Ariad Pharmaceuticals, ridaforolimus
FDA approves Anika Therapeutics arthritis drug
Yahoo/Reuters
Tuesday, February 25, 2014 - 6:14pm
tags:
Anika, FDA, osteoarthritis of the knee, Monovisc, DePuy, JNJ
AbbVie, Amgen and Roche most vulnerable to biosim rivals, Moody's says
Fierce Pharma
Tuesday, February 25, 2014 - 3:58pm
tags:
AbbVie, Amgen, Roche, biosimilars
Clock Is Ticking For AstraZeneca
Forbes
Tuesday, February 25, 2014 - 3:57pm
tags:
AstraZeneca, dulaglutide, GSK, Eli Lilly, Bydureon, diabetes
One Reason the Biotech Boom Won’t Turn to Bust
Barron's
Tuesday, February 25, 2014 - 11:17am
tags:
biotech, Biogen Idec, Regeneron
Two Years Less Exclusivity Is the Least of Amarin's Issues
Motley Fool
Tuesday, February 25, 2014 - 11:15am
tags:
Amarin, exclusivity, Vascepa
No Looking Back for Regeneron's Eylea
Yahoo/Zacks.com
Tuesday, February 25, 2014 - 11:05am
tags:
Regeneron, Eylea, BRVO
Is NPS Pharmaceuticals The Next Alexion?
Seeking Alpha
Tuesday, February 25, 2014 - 11:03am
tags:
NPS Pharmaceuticals, Alexion, NPSP795, Gattex

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.